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Abstract
Tumors are heterogeneous in the sense that they consist of multiple subpopulations of cells,
referred to as subclones, each of which is characterized by a distinct profile of genomic vari-
ations such as somatic mutations. Inferring the underlying clonal landscape has become an
important topic in that it can help in understanding cancer development and progression,
and thereby help in improving treatment. We describe a novel state-space model, based on
the feature allocation framework and an efficient sequential Monte Carlo (SMC) algorithm,
using the somatic mutation data obtained from tumor samples to estimate the number of
subclones, as well as their characterization. Our approach, by design, is capable of handling
any number of mutations. Via extensive simulations, our method exhibits high accuracy, in
most cases, and compares favorably with existing methods. Moreover, we demonstrated
the validity of our method through analyzing real tumor samples from patients from multiple
cancer types (breast, prostate, and lung). Our results reveal driver mutation events specific
to cancer types, and indicate clonal expansion by manual phylogenetic analysis. MATLAB
code and datasets are available to download at: https://github.com/moyanre/tumor_clones.
Introduction
In most cases, tumors develop from a single population of cells. Accumulated somatic muta-
tions confer selective advantages to the cells in this population over others [1], and then this
population of cells continues to proliferate. As more somatic mutations are acquired, some
tumor cells gain further survival advantages, which leads to an expansion from a single popula-
tion to multiple subpopulations. As a result, tumors are heterogeneous in nature [2, 3] and
contain multiple subpopulations of cancerous cells, each with a unique mutational profile [4–
6], referred to as tumor subclones [2, 7, 8]. The importance of analyzing the tumor subclonal
structure and evolutionary progress has been recognized, considering the potential of elucidat-
ing the underlying mechanisms of cancer progression, metastatic spread and therapy response
[9–11].
Characterizing tumor heterogeneity with subclonal structure, using next-generation
sequencing (NGS) data is a well-studied problem [12], and various computational methods
have been proposed for estimating the subclonal structure in the tumor samples [13–17].







Citation: Ogundijo OE, Zhu K, Wang X,
Anastassiou D (2019) A sequential Monte Carlo
algorithm for inference of subclonal structure in
cancer. PLoS ONE 14(1): e0211213. https://doi.
org/10.1371/journal.pone.0211213
Editor: Xiang Li, Janssen Research and
Development, UNITED STATES
Received: June 2, 2018
Accepted: January 3, 2019
Published: January 25, 2019
Copyright: © 2019 Ogundijo et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All datasets are
available from: https://github.com/moyanre/tumor_
clones.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
Some methods approach this estimation problem by first grouping the mutations into clusters,
and then performing phylogenetic analysis to obtain the mutational profiles of the various dis-
tinct subclones in the samples [14–17]. A more direct approach bypasses the clustering stage
by modeling, in straightforward manner, the NGS data with a feature allocation model [13,
18–20]. Basically, with this setup, the problem is reduced into a form of matrix factorization
[21], where the observed variant allele frequency (VAF) is deconvolved into matrices of geno-
types of subclones and the proportion of genotypes in the samples [13, 18, 20]. However, meth-
ods in this category are faced with several issues, such as the assumption that the number of
subclones have to be fixed before analysis [13, 19], and the fact that only a few mutations can
be analyzed [19].
Here, we propose an algorithm for estimating the number, genotypes and the proportion of
subclones, employing a more general model that better explains the inherent heterogeneity in
tumor samples by allowing more categories for the genotypes, so as to capture the three possi-
ble genotypes in a diploid individual. Specifically, 0 for homozygous wild-type, 0.5 for hetero-
zygous mutant and 1 for homozygous mutant. Our approach, which is based on the state-
space formulation of the feature allocation model, employs the SMC [22–24] algorithm for
estimating the model parameters. The proposed SMC algorithm takes advantage of the cate-
gorical Indian buffet process (cIBP) [20], a sequential procedure that describes the prior distri-
bution of the general (Q + 1)-ary categorical matrix, in modeling the genotypes of subclones.
Because the proposed algorithm processes the observed VAF data sequentially, it offers the
flexibility of being able to handle any number of mutations without encountering computa-
tional issues. More specifically, SMC, a powerful recursive filtering algorithm [21, 25, 26],
computes, in a flexible manner, the posterior probability density function (PDF) of the hidden
state every time a measurement is observed, approximating the posterior distributions of the
variables of interest with a set of properly weighted samples, which we will refer to as particles
to distinguish between random samples from a distribution and tumor samples.
Over the simulated datasets, we compare our algorithm with BayClone [20], a Markov
chain Monte Carlo (MCMC) based algorithm, often employed when estimating model param-
eters in tumor heterogeneity [19], and Clomial [13], an expectation maximization (EM) based
algorithm. Similar to the our modeling method, BayClone considers the three possible geno-
types in a diploid individual. Although the modeling approach in Clomial only considers
homozygous wild-type and heterozygous mutant (a common modeling consideration in the
analysis of tumor heterogeneity [19]), it employs EM, a different inference algorithm, to esti-
mate the model parameters. Invariably, our simulations compare the performance of three dif-
ferent algorithms: SMC, MCMC and EM. In terms of the accuracy of the estimates of model
parameters, the proposed SMC method compares favorably with other methods.
The remainder of this paper is organized as follows. In Section 2, we describe the system
model and problem formulation. In Section 3, we validate the proposed algorithm with simu-
lated data, as well as real data obtained from solid tumors across three major cancer types:
prostate adenocarcinoma (PRAD), breast invasive ductal carcinoma (IDC) and lung adenocar-
cinoma (LUAD). Finally, Section 4 concludes the paper.
Notation-wise in this paper, we denote a vector and a matrix by boldface lower and upper
case letters, respectively; p(�) and p(�|�) denote a probability density function (PDF) and a con-
ditional PDF, respectively; P(�) and P(�|�) denote a probability and conditional probability
mass function, respectively;N ðm; s2Þ denotes a Gaussian distribution with mean μ and stan-
dard deviation σ; Binomial(n, p) denotes a binomial distribution having n number of trials and
p probability of success; Poisson(λ) denotes a Poisson distribution with mean parameter λ;
Gamma(a0, b0) denotes a gamma distribution with shape parameter a0 and rate parameter b0;
Subclone inference in cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0211213 January 25, 2019 2 / 21
Beta(a1, b1) denotes a beta distribution with shape parameters a1 and b1 and Dirichlet(α)
denotes a Dirichlet distribution with a vector of concentration parameters α.
System model and problem formulation
System model
In our model, we assume that a tumor is heterogeneous i.e., it consists of multiple sub-popula-
tions, referred to as subclones. Each subclone is assumed to have a unique genotype and at
each characterizing mutation locus, we assume that one of the following is the case: (i) none of
the alleles is mutated (homozygous wild-type), designated with genotype 0, (ii) one of the
alleles is mutated, designated with genotype 0.5, and (iii) both alleles are mutated, designated
with genotype 1. Our goal is to estimate the number of subclones, genotypes of all the sub-
clones, and the proportion of each subclone in the tumor samples. To do this, we assume an
availability of DNA sequencing data designed to probe tumor heterogeneity. This dataset
comes in form of two matrices Y and V of equal dimension T × S. T and S denote the numbers
of loci and tumor samples, respectively, and the elements of the two input matrices, yts and vts,
t = 1, . . ., T, s = 1, . . ., S, denote the number of reads that bear a variant sequence and the total
number of reads, respectively. We model the matrix of variant counts as follows:
yts �
ind:Binomialðvts; ptsÞ; t ¼ 1; . . . ;T; s ¼ 1; . . . ; S; ð1Þ
where pts is the success probability of obtaining yts reads from the total reads vts at locus t in
sample s, t = 1, . . ., T, s = 1, . . ., S. pts is interpreted as the weighted sum of the genotypes of all





where C denotes the unknown number of distinct subclones in the tumor samples, ztc 2 {0,
0.5, 1} denotes the possible three states for the allelic genotypes at locus t in subclone c and wcs
denotes the proportion of subclone c in tumor sample s. In addition, the first term in (2)
accounts for experimental and data processing noise, where p denotes the relative frequency of
variant reads produced as error from upstream data processing and usually takes a small value,
close to zero; w0s absorbs the noise left unaccounted for by {w1s, . . ., wCs} [20].
In (2), for all the genomic loci, we arrange the genotypes of all subclones in a T × C ternary
matrix Z and we refer to this as the matrix of genotypes. Similarly, we arrange all the p’s in a T-
dimensional column vector p, and arrange the respective proportions w0s and wcs, for all sam-
ples, in a C0 × S matrix W and refer to this as the matrix of proportions, where each column of
the proportion matrix sums to unity, and C0 = C + 1. Then (2) can be expressed as a matrix fac-
torization problem, such that:
Pts ¼ Z
0 �W; ð3Þ
where pts, an element of Pts, denotes the expected VAF at locus t in sample s and Z0 = [p Z].
Given the input read count data, we next describe the proposed SMC algorithm to perform a
joint inference on the number of distinct subclones in the tumor samples, the genotype of each
subclone and the proportion of each genotype in the tumor samples.
Algorithm 1 Sample P(zt|Zt−1, α, β) using the categorical Indian buffet process (cIBP)
1: Z  Zt−1
2: β� = 2β
3: if t = 1 then
Subclone inference in cancer
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4: Sample Cnewt � PoissonðaÞ
5: for c ¼ 1; . . . ;Cnewt do


















9: C+  Number of non-zero columns in Z
10: for c = 1, . . ., C+ do
11: mc1  
Pt  1
r¼1 Iðzrc ¼ 0:5Þ
12: mc2  
Pt  1
r¼1 Iðzrc ¼ 1Þ
13: mc  mc1 + mc2
14: ztc  





































17: for d ¼ ðCþ þ 1Þ; . . . ; ðCþ þ Cnewt Þ do



















In this section, we succinctly describe our state-space formulation of the deconvolution prob-
lem we set up in (3) with the details described in S1 File. At time step t, we consider the tth row
of the input read count matrices, as the observation at that particular time. Subsequently,
because we are interested in constructing the ternary genotype matrix Z (with an unknown
number of columns) sequentially, one row after the other, using the cIBP (details in the S1
File), we consider the tth row of the genotype matrix as the hidden state at time t, and then, the
proportion of the subclones in the tumor samples, matrix W and p are considered as the
parameters of our state-space model. Thus, the state transition equation is stated as follows:
PðztjZt  1; a; bÞ; ð4Þ
where Zt−1 denotes the previous t − 1 rows in the genotype matrix Z, α and β are constants, to
be supplied by the user. The reasonable range for both constants are discussed in S1 File and
the algorithm to sample from (4) is presented in Algorithm 1 as follows.
The genotype matrix at time step t, Zt is implicitly constructed from the genotype matrix in
the previous time step t − 1, Zt−1. In the construction process, if new non-zero column(s) is/
are introduced in Zt, then the subclone proportion matrix W would be augmented with an
equivalent number of rows. Thus, W requires some re-parameterization to account for such
change in dimension. Specifically, we rewrite wcs ¼ ycs=
PC
c0¼0 yc0s. This implies that instead of
estimating wcs directly, we estimate θcs, and then obtain wcs from the estimates of θcs. Such re-
parameterization ensures that each column of W sums to unity at every time step.
Subclone inference in cancer
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Moreover, since we are interested in the final estimates of the model parameters W and
p, we create artificial dynamics for these parameters using the random walk model as fol-
lows:
�t � pð�tj�t  1Þ ¼ N ð�t  1; s2Þ;
�t 2 fp; ycs; c ¼ 0; 1; . . . ;C; s ¼ 1; . . . ; Sg;
ð5Þ
where σ denotes the standard deviation. Hence, (4) and (5) fully describe the system state
transition. Similarly, the observation at time t is given by:






where yt denotes the observation at time t (which is conditionally independent of the
previous observations Yt−1 given the state zt), i.e., the tth row of Y. (6) describes the
measurement model for the system. Finally, (4)–(6) completely describe our proposed state-
space model for estimating the number, genotypes and proportions of subclones in tumor
samples.
Algorithm 2 SMC algorithm for inferring subclonal structure
Input: Y, V.









2: for t = 1, . . ., T do
3: for i = 1, . . ., N do
4: Sample zit from Z
i
t  1 using Algorithm 1.
5: n1  number of columns in Zit  1
6: n2  length of zit
7: d  (n2 − n1)













13: Sample Wit using (5).
14: Sample new rows of Wit from the prior in (9).
15: end if
16: Calculate ~wit using (8)
17: end for
18: Normalize the weights
19: Perform resampling
20: end for
Subclone inference in cancer
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i¼1) consist of varying number of columns and rows,
respectively. Estimate of the number of subclones is obtained from
the number of columns of the genotype particles (equivalently the
number of rows of the proportion particles). Details of how the
posterior estimates of all the unknown variables are obtained from
the final particles and weights, using the procedures highlighted
in [20, 27], are discussed in S1 File.
The SMC algorithm
We summarize the SMC filtering framework employed to make inference about the number
of subclones, genotype of each subclone and the proportion of each subclone in the tumor
samples, which are the states and the parameters of our proposed state-space model. Details of
our proposed algorithm are presented in S1 File.
Consider the general dynamic system with hidden state variable xt, in our case consisting of
categorical variables zt and continuous variables φt,
�t 2 fpt0; y
t
cs; c ¼ 0; 1; . . . ;C; s ¼ 1; . . . ; Sg, and measurement variable yt, where there is an
initial state model p(x0), and 8t� 1, a state transition model given in (4) and (5) and an obser-
vation model given in (6). The sequence Xt = {x1, x2, . . ., xt} is not observed and we want to
estimate it for each time step, given that we have the observations Yt = {y1, y2, . . ., yt}. Our goal
is to approximate the posterior distribution of states p(Xt|Yt) using samples drawn from it.
Getting such samples from p(Xt|Yt) is not feasible, at least in our model. However, we can still
implement an estimate using N samples (particles), fXitg
N
i¼1, taken from another distribution, q
(Xt|Yt), whose support includes the support of p(Xt|Yt) (importance sampling theorem), and
each particle is accompanied by a weight wi such that
PN
i¼1 wi ¼ 1 (see S1 File for detail).




i¼1 is said to be properly weighted with respect to the distribution p(Xt|






tÞ; where dðuÞ ¼






Next, the importance sampling theory is generalized to obtain a sequential algorithm as fol-





i¼1 from the importance distribution q(Xt−1|Yt−1) to approximate the target poste-
rior distribution p(Xt−1|Yt−1). At time step t, we can now draw particles fXitg
N
i¼1 from the
importance distribution q(Xt|Yt) as follows: (i) draw new state particles for the time step t as
xit � pðxtjX
i










i¼1. Then, the unnorma-
lized weights at time step t are obtained from the normalized weights at time step t − 1 and the












and the unnormalized weights ~wit are normalized to sum to unity. However, since the variance
of the weights increases over time, we perform resampling at every time step, owing to the
choice of our importance distribution (see S1 File for detail) [28–31], discarding the ineffective
particles and multiplying the effective ones. The resampling procedure [25] is briefly summa-
rized as follows:
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• Interpret each weight wit as the probability of obtaining the particle index i.
• Draw N particles from the discrete probability distribution fwitg and replace the old particle
set with this new one.
• Set all weights to the constant value wit ¼ 1=N.
Finally, the proposed SMC algorithm for estimating the states and the parameters of our
state-space model is presented in Algorithm 2. The algorithm is initialized by taking samples
from the prior distributions of the parameters. We assume the following:
y0s �
i:i:d Gammaða0; 1Þ; s ¼ 1; . . . ; S;
ycs �
i:i:d Gammaða1; 1Þ; s ¼ 1; . . . ; S; c ¼ 1; . . . ;C; and
p � Betaða00; b00Þ;
ð9Þ
such that wcs ¼ ycs=
PC
c0 ¼0 yc0 s and consequently,
PC
c0 ¼0 wc0 s ¼ 1. We report the posterior esti-
mates of all the unknown variables using the procedure highlighted in [27], with the details
discussed in S1 File.
Results
Application to simulated datasets
To validate our method, we generated multiple simulated datasets for different combinations
of the number of subclones C, average sequencing depth r, sample size S and the number of
loci T. Specifically, we considered C 2 {3, 4, 5} subclones, S 2 {3, 4, . . ., 15} tumor samples, we
fixed the average sequencing depth r = 100 and also the number of loci, T = 20. For each com-
bination of the number of subclones, sample size, average sequencing depth and number of
loci, we produced 10 datasets as follows: (i) the total read count at locus t in sample s, i.e., vts is
generated from Poisson(r), (ii) each column of the proportion matrix is independently gener-
ated from Dirichlet([a0, a1, . . ., aC]), a0 = 0.1 and ac; c 2 {1; . . ., C} is randomly chosen from
the set {2, 4, 5, 6, 7, 8}, (iii) each entry of the genotype matrix is independently generated from
Discrete([0.5 0.1 0.4]) and set p = 0.02, (iv) the success probability pts is computed following
(2), and then, (v) yts, the variant count, is generated as an independent sample from Binomial
(vts, pts).
To quantify the performance of the proposed algorithm, we define the following metrics:
genotype reconstruction error (eZ), proportion error (eW) and the error of the success proba-



























However, because this is a blind decomposition, it is not clear a priori which column of the
estimated genotype matrix Z^ corresponds to which column of the true genotype matrix Z. We
resolve this by calculating eZ with every permutation of the columns of Z^ and then select the
permutation that results in the smallest value. The selected permutation is then used in com-
puting eW and epts .
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For every combination of the number of subclones, sample size, average sequencing depth
and number of loci, we computed the average and the standard deviation of the genotype
error, proportion error and the error of the success probabilities over the 10 datasets in each
group. The results are presented in Fig 1(a)–1(c) where the standard deviation is the vertical
line above and below the average value in the errorbar plots. These results show that the per-
formance of the proposed algorithm improves with an increase in the number of tumor sam-
ples. Also, when the number of subclones in the samples is minimal, estimation of model
parameters becomes more accurate. For T = 20, r = 100, S = 10 and C 2 {3, 4, 5}, we present, in
Fig 1(d)–1(f), the estimated posterior distributions of C. In the three cases, the maximum a
posteriori (MAP) estimates of C (marked with red vertical lines) are 3, 4 and 5. It should be
noted that in the implementation of the proposed algorithm, the estimates of other model
parameters are conditional on the MAP estimate of C. This is discussed further in S1 File.
Further, we compared our proposed algorithm with BayClone [20], an algorithm with simi-
lar model assumption and also with Clomial [13]. For the comparison with Clomial, the true
genotype matrix only includes two categories i.e. 0 for an absence of mutation and 0.5 for the
presence of mutation and each entry of the matrix is generated from Discrete([0.3 0.7]). In
computing the errors for Clomial, we viewed a 1 in the estimated genotype matrix as 0.5 for
consistency with the true matrix. The results of the simulated data for three subclones, differ-
ent sample size, average sequencing depth of 100 and 50 loci are presented in Figs 2 and 3.
Fig 3 does not include the error of success probability because Clomial only estimates the
genotype and the proportion matrices. The runtime for the proposed algorithm, BayClone and
Clomial for sample size S = 5, number of subclones C = 3, average sequencing depth r = 100
and 50 loci are 782, 1454 and 768 seconds, respectively, on a 3.5 GHz Intel 8 cores running
MATLAB. Lastly, we investigated the performance of the algorithms when the number of loci
is very large since this is often a source of computational issue in some of the existing methods
[19]. The result for 2000 and 5000 genomic loci are presented in Table 1 (the results for 2000
and 5000 loci are with and without brackets, respectively). For the proposed algorithm, we
noticed a slight improvement in the estimate of the proportion when the number of loci is
large. In the case of the two other algorithms, we observed a slight increase in the genotype
and proportion errors with large genomic loci.
Application to solid tumor datasets
Data pre-processing. The somatic mutation data of real solid tumors come from the
American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Informa-
tion Exchange (GENIE) project [1]: Version 2.0.0, which are accessible on the Sage Synapse
platform (with Synapse ID: syn11310744) [32]. We performed three filtering criteria before
creating the final data set to run our algorithm. (i) The data release includes genomic records
collected by eight participating institutions. To control the batch effect, we selected samples
from Memorial Sloan Kettering (MSK) Cancer Center given the fact that they provide
matched tumor-normal (rather than tumor-only) sequence data and their sample size is the
largest. (ii) We selected patients who have at least three samples with somatic mutation data.
(iii) We further filtered out samples so that the remaining data contain information for at least
three patients for each cancer type. As a result, the data set we retained include 36 samples (of
10 patients) with prostate adenocarcinoma (PRAD), 18 samples (of 6 patients) with breast
invasive ductal carcinoma (IDC) and 9 samples (of 3 patients) with lung adenocarcinoma
(LUAD).
To create the input count matrices for the proposed algorithm, we combined count data of
all the samples from the same patient by the union of their mutated gene symbols. Regarding
Subclone inference in cancer
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Fig 1. Simulation results for the proposed algorithm. (a), (b) and (c): Plots of the genotype error (eZ), proportion error (eW) and error
of success probability (epts ) versus different sample sizes for subclones C 2 {3, 4, 5}. (d), (e) and (f): Posterior distributions of C, for C = 3,
4, and 5.
https://doi.org/10.1371/journal.pone.0211213.g001
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Fig 2. The proposed algorithm and BayClone. (a), (b) and (c): Plots of the genotype error (eZ), proportion error (eW)
and error of success probability (epts ) versus different sample sizes for the proposed algorithm and BayClone.
https://doi.org/10.1371/journal.pone.0211213.g002
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Fig 3. The proposed algorithm and Clomial. (a) and (b): Plots of the genotype error (eZ) and proportion error (eW)
versus different sample sizes for the proposed algorithm and Clomial.
https://doi.org/10.1371/journal.pone.0211213.g003
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the entries for which the mutation of the corresponding gene was not detected in some sam-
ples, we imputed the values with the average counts of the matched normal samples. For
instance, we assume that there are three samples (A, B, C) from a specific patient and samples
A and B have mutations at gene G while sample C does not. In the combined total (or alter-
ation) count matrix of this patient, we used the average of total (or alteration) counts for gene
G of the matched normal samples of A and B to be the imputed count of C for gene G in the
combined matrices.
Inferred subclonal structure and phylogenetic trees. We illustrated the use of our algo-
rithm on the three solid cancer types: PRAD, IDC and LUAD. We applied our algorithm on
the data of every patient, resulting in the inferred subclonal landscape, which contains the
information of the genotypes, the proportions of each subclone as well as the possible phyloge-
netic tree. Some of the model parameter estimates are presented and the others, including the
posterior distributions of the number of subclones, are in S1 Tables and S1 Figs.
A phylogenetic tree depicts the evolutionary history of cancer progression. Based on the
inferred subclonal genotypes, drawing insight from the approach in [13], we manually con-
structed a phylogenetic tree for each patient, in which the root is always the normal subclone,
each node represents a subclonal population, and the mutations that occurred between the
parent and the offspring nodes are shown on the edges. Moreover, since our algorithm is able
to identify both heterozygous and homozygous mutations, we annotated those mutations
which were inferred as homozygous. We reasoned that investigating the subclonal results com-
bined with the phylogenetic characteristics has the potential to provide evidence for the valid-
ity of our method.
Driver mutations found on edges connected to the root of the phylogenetic trees. We
observed that genes with well known driver mutations for one cancer type are located on the
edges that are connected to the root of the phylogenetic tree of patients with that cancer. This
is consistent with the fact that are somatic mutations in a gene that confer a selective advantage
on cancer cells, which are believed to be involved in cancer initiation and clonal expansions
[33].
Specifically, in each of the six instances of IDC, we found that either gene PIK3CA or gene
AKT1 is placed on the edge directly connected to the neutral/normal subclone. Two examples
are shown in Fig 4 (IDC_0000525) and Fig 5 (IDC_0000690) and the corresponding estimated
genotype matrices are shown in Tables 2 and 3, respectively. The inferred results for other IDC
patients can be found in S1 Figs and S1 Tables. Somatic mutations occurring in oncogenes
PIK3CA and AKT1 have been widely reported in breast cancer [34–36]. PIK3CA is the most
frequently mutated gene found in breast cancer [37], and it is an integral component of the
phosphatidylinositol 3 kinase (PI3K) signaling pathway. AKT1, one of the three isoforms of
the protein kinase AKT, is also a mediator in the downstream of the PI3K pathway and it plays
a key role in promoting cell survival by inhibiting apoptosis. Its over-activation has been impli-
cated in tumorigenesis [35–38]. The dysregulation of the PI3K/AKT pathway has been demon-
strated in different solid tumors including breast cancer, and it has been suggested that this
Table 1. Comparison of algorithms on large datasets.
Genotype error Proportion error Runtimes (seconds)
Proposed algorithm 0.0040 [0.0050] 0.0121 [0.0116] 2.754e4 [5.707e4]
BayClone 0.1000 [0.0950] 0.0632 [0.0724] 5.032e4 [1.363e5]
Clomial 0.0850 [0.0500] 0.0548 [0.0550] 2.736e4 [5.688e4]
https://doi.org/10.1371/journal.pone.0211213.t001
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dysregulation is associated with the increased mutations in pathway genes PIK3CA and AKT1
[36, 39].
In the case of LUAD, KRAS and EGFR have mutations found prevalent in patients [40–42].
Despite the small number of patients, the constructed phylogenetic trees showed consistent
results. First, among the three LUAD patients, two of them harbor somatically mutant KRAS
and the remaining one has mutation in EGFR, which also reflects the well-known mutual
exclusiveness of these two driver mutations [43]. Fig 6 and Table 4 display the case of patient
LUAD_0000978, from which we can find that KRAS is marked on the edge connected to the
Fig 4. Phylogenetic tree for IDC_0000525. Constructed phylogenetic tree for patient IDC_0000525.
https://doi.org/10.1371/journal.pone.0211213.g004
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Fig 5. Phylogenetic tree for IDC_0000690. Constructed phylogenetic tree for patient IDC_0000690.
https://doi.org/10.1371/journal.pone.0211213.g005
Table 2. Estimated genotype for IDC_0000525.
Gene name C1 C2 C3 C4
TP53 0 0.5 0 0.5
AKT1 0.5 0.5 0.5 0.5
RUNX1 0.5 0 0.5 0
POLE 0 0.5 0 0.5
FANCC 0 0 0 0.5
STK11 0 0 0 0.5
EP300 0 0 0 0.5
RB1 0 0.5 0 0
FOXP1 0.5 0 0.5 0
SHQ1 0 0.5 0 0
https://doi.org/10.1371/journal.pone.0211213.t002
Table 3. Estimated genotype for IDC_0000690.





Subclone inference in cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0211213 January 25, 2019 14 / 21
root in the phylogenetic tree, indicating its oncogenic role. A previous study analyzing somatic
mutation data of non-small cell lung cancer by a different method also found that KRAS and
EGFR mutations were present in the founder clone in their results, suggesting that it is likely
that these mutations are initiating events for lung cancer [40].
Fig 6. Phylogenetic tree for LUAD_0000978. Constructed phylogenetic tree for patient LUAD_0000978.
https://doi.org/10.1371/journal.pone.0211213.g006
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Genotype assignments validated by the tree structures. One of the advantages of the
proposed algorithm is that for each gene, it can consider three different categories of genotype:
wild-type, heterozygous and homozygous. This feature was validated by analyzing the hierar-
chical structure of the inferred phylogenetic trees. Given that one of our assumptions is that a
mutation never disappears in the entire phylogeny, if a mutant gene were assigned different
genotypes in different subclones, the subclone(s) with homozygous mutations should be
descendant(s) of the subclone(s) with heterozygous mutations. This implies that the paternal
and the maternal alleles (or vice versa) of this gene became mutated consecutively, along the
clonal evolution. Such situations apply to three cases of PRAD patients: PRAD_0000655,
PRAD_0003101, PRAD_0003511 (Fig 7), constructed from the inferred genotype matrices in
S1 Tables. For example, in patient with ID “PRAD_0003101”, the inferred decomposition
results in S1 Tables showed that there are two subclones (referred to as subclone 1 and sub-
clone 2, respectively) in addition to the normal one. Both subclone 1 and subclone 2 harbor
mutations in gene PTEN; however, the respective genotypes are different: “0.5” (i.e. heterozy-
gous) for subclone 1 while “1” (homozygous) for subclone 2. The constructed phylogenetic
tree revealed concordant result (Fig 7(b)) that subclone 2 is the offspring node of subclone 1,
suggesting that an additional mutation event occurred in PTEN during this clonal expansion
which resulted in the change in genotype.
Inferred subclonal proportions along the phylogeny indicate tumor progression. Fur-
thermore, the inferred subclonal proportions along with the tree structures provide more
evidence to validate our algorithm. For the same patient that we discussed above i.e.,
“PRAD_0003101”, there are three metastatic samples available among which one was obtained
when the patient was 68 years old (referred to as M1) and the other two were obtained when
he was 69 years old (referred to as M2 and M3). We found that the proportions of subclone 2
in M2 (96%) and M3 (86%) samples are much higher than the one for M1 sample (29%), and
cases for subclone 1 to the contrary S1 Tables. Meanwhile, we also observed similar results for
another patient with ID “PRAD_0001204”, who has two primary tumor samples and one met-
astatic sample (S1 Tables and S1 Figs). In this case, subclone 1 descends from subclone 2, and
the highest proportion of subclone 1 can be found in the metastatic sample, which was also
obtained when the patient was older. These findings imply that as the patient aged or the can-
cer metastasized, the mutations specific to the descendant subclone gained cells survival
advantage, promoting cell proliferation, and hence resulted in the increasing proportion of the
subclone in samples.
Discussion
The inherent heterogeneity in tumor samples often results in setbacks when cancer patients
undergo treatment. The samples consist of different subpopulations of cancerous cells, each
Table 4. Estimated genotype for LUAD_0000978.
Gene name C1 C2 C3 C4
SMAD4 1 0 0 0
PTPRT 0.5 0 0 0
RAD54L 1 0 0 0
APC 0.5 0.5 0 0
GRIN2A 0.5 0.5 0 0
PAK7 0.5 0 0 0
MET 0.5 0.5 0.5 0
KRAS 0 0 0 0.5
https://doi.org/10.1371/journal.pone.0211213.t004
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Fig 7. Phylogenetic trees for patients with PRAD. Constructed phylogenetic tree for patients: (a) PRAD_0000655,
(b) PRAD_0003101 and (c) PRAD_0003511.
https://doi.org/10.1371/journal.pone.0211213.g007
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characterized by a distinct mutational profile. Inference of these profiles and the proportion of
each subpopulation in the samples can improve personalized medicine e.g. preventing cancer
relapse and helping in cancer prognosis. We proposed an efficient sequential algorithm for
estimating the mutational profile of each cancer cell subpopulation and their respective pro-
portions in the tumor samples. With simulated datasets, we performed experiments to validate
our algorithm. We applied our algorithm to real tumor samples, covering three solid cancer
types, PRAD, IDC, and LUAD.
By analyzing the inferred genotype landscape results, we found evidence supporting the
validity of our method in several ways. For example, many well-known driver mutations spe-
cific to cancer types were found in the edges directly connected to the root in the inferred phy-
logenetic tree. The position of these somatic mutations indicates their roles in cancer initiation
and expansion. For example, somatic mutations in genes PIK3CA and AKT1 were identified
as driver events for breast cancer, suggesting malfunction of PI3K/AKT pathway in cancer
[39]. Such characteristics were consistently observed across different patients included in this
study.
We also evaluated our algorithm by investigating the phylogenetic tree structures, which
could imply the cancer progression history in patients. The algorithm is able to distinguish
the genotype of a mutation among wild-type, heterozygous and homozygous. Consistent
with one of our assumptions that a somatic mutation will not disappear, our results revealed
that if a mutant gene were assigned different genotypes in different subclones, the subclone
(s) with homozygous mutations was always the descendant(s) of the subclone(s) with
heterozygous mutations, indicating the order of mutation events on different alleles during
the clonal expansion. Moreover, we observed increasing proportions of leaf subclones
in more advanced samples than less advanced ones, such as metastatic samples versus pri-
mary samples, from the identical patients, suggesting the proliferation of cells in these sub-
clones due to the survival advantages by acquiring more mutations during the cancer
progression [1].
Lastly, the proposed algorithm can handle any number of mutations in an accurate and
computationally efficient manner.
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